Targeting the spliceosome : A new therapeutic strategy to counteract chemotherapy resistance in lung cancer?
Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved..
Lung cancer is the first cancer-related cause of death worldwide. This is in partially due to therapeutic resistance, which occurs in around 70% of patients, especially those receiving platinum salts, the gold-standard chemotherapy. The massive deregulation of alternative transcript splicing processes observed in many cancers has led to the development of a new class of pharmacological agents aimed at inhibiting the activity of the splicing machinery (spliceosome). The molecular mechanisms by which these inhibitors act remain largely unknown, as do the benefits of using them in combination with other therapies. In this context, our work is focused on an inhibitor of the SRPK1 kinase, a major regulator of the spliceosome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 41(2024), 4 vom: 08. Apr., Seite 294-298 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Cibler le splicéosome : une nouvelle stratégie thérapeutique pour contrecarrer la résistance à la chimiothérapie dans les cancers du poumon ? |
|---|
| Beteiligte Personen: |
Shreim, A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2024.02.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369508149 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369508149 | ||
| 003 | DE-627 | ||
| 005 | 20240415233352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240310s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2024.02.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM369508149 | ||
| 035 | |a (NLM)38461087 | ||
| 035 | |a (PII)S0761-8425(24)00143-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Shreim, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting the spliceosome |b A new therapeutic strategy to counteract chemotherapy resistance in lung cancer? |
| 246 | 3 | 3 | |a Cibler le splicéosome : une nouvelle stratégie thérapeutique pour contrecarrer la résistance à la chimiothérapie dans les cancers du poumon ? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Lung cancer is the first cancer-related cause of death worldwide. This is in partially due to therapeutic resistance, which occurs in around 70% of patients, especially those receiving platinum salts, the gold-standard chemotherapy. The massive deregulation of alternative transcript splicing processes observed in many cancers has led to the development of a new class of pharmacological agents aimed at inhibiting the activity of the splicing machinery (spliceosome). The molecular mechanisms by which these inhibitors act remain largely unknown, as do the benefits of using them in combination with other therapies. In this context, our work is focused on an inhibitor of the SRPK1 kinase, a major regulator of the spliceosome | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer du poumon | |
| 650 | 4 | |a Chemotherapy resistance | |
| 650 | 4 | |a Epissage de l’ARN | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a RNA splicing | |
| 650 | 4 | |a Résistance à la chimiothérapie | |
| 650 | 4 | |a SRPK1 | |
| 650 | 7 | |a SRPK1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a Protein Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Gazzeri, S |e verfasserin |4 aut | |
| 700 | 1 | |a Eymin, B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 41(2024), 4 vom: 08. Apr., Seite 294-298 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:08 |g month:04 |g pages:294-298 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2024.02.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 4 |b 08 |c 04 |h 294-298 | ||